Thyrocare Resubmits Q1 FY27 Unaudited Financial Results
Thyrocare Technologies Limited resubmitted its unaudited standalone and consolidated financial results for Q1 FY27. Standalone revenue from operations was ₹225.66 crore, with profit after tax at ₹50.17 crore. Consolidated revenue from operations stood at ₹240.02 crore, with profit after tax of ₹52.19 crore.
This is a procedural resubmission of already disclosed financial results, hence it has minimal impact on the company's stock or business operations.
The announcement is a routine resubmission of financial results in a required format and does not contain new financial performance information or strategic updates that would alter the company's outlook.
Thyrocare Technologies Limited has resubmitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This resubmission is in response to an email from the National Stock Exchange (NSE) requiring the financial results in a machine-readable format.
The company had previously submitted these results on July 23, 2026, following a Board Meeting. The resubmitted documents include the financial results along with the respective Limited Review Reports from Price Waterhouse Chartered Accountants LLP.
For the quarter ended June 30, 2026, standalone revenue from operations stood at ₹225.66 crore, with a total revenue of ₹229.17 crore. Profit after tax was ₹50.17 crore, and basic earnings per share were ₹3.15.
On a consolidated basis, revenue from operations was ₹240.02 crore, and total revenue was ₹244.17 crore. Profit after tax attributable to owners of the company was ₹52.19 crore, with basic earnings per share at ₹3.23.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.